These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3230974)

  • 21. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
    Heinze T; Lichtenegger W
    Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carcinoembryonic antigen(s) in liver disease. I. Clinical and morphological studies.
    Moore T; Dhar P; Zamcheck N; Keeley A; Gottlieb L; Kupchik HZ
    Gastroenterology; 1972 Jul; 63(1):88-94. PubMed ID: 4115635
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tumor markers in breast cancer].
    Harada Y; Ohuchi N; Ishida T; Ohnuki K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
    Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
    Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the BT-1 serum assay for breast cancer.
    Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
    Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [MSA--a new sensitive tumor marker in breast carcinoma].
    Zahm DM; Greinke C; Nöschel H
    Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum monoamine oxidase (MAO) in the differential diagnosis of chronic liver disease. I].
    Averna MR; Genova G; Montalto G; Labisi M; Mazza G; Migneco G; Tripi S; Notarbartolo A
    Boll Soc Ital Biol Sper; 1984 Sep; 60(9):1671-7. PubMed ID: 6525286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Significance of laparoscopy in the field of diagnosis].
    Stadelmann O; Miederer SE; Müller R
    Schweiz Rundsch Med Prax; 1971 Nov; 60(46):1540-2. PubMed ID: 4257773
    [No Abstract]   [Full Text] [Related]  

  • 32. [Immunochemical diagnostis of gastrointestinal diseases (with special consideration of tumor immunology)].
    Tilz ZP; Buffe D; Rimbaut C
    Med Klin; 1973 Jul; 68(30):994-9. PubMed ID: 4125217
    [No Abstract]   [Full Text] [Related]  

  • 33. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
    Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
    Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tumor markers in focal and diffuse liver diseases].
    Kasatkin IuN; Ametov AS; Mit'kov VV; Sevast'ianov SI; Zarudin VV
    Med Radiol (Mosk); 1984 Apr; 29(4):39-43. PubMed ID: 6201693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of tissue polypeptide specific antigen as a marker in liver diseases.
    Cetin T; Oğuz A; Algan P; Yildirim IS
    Turk J Gastroenterol; 2003 Sep; 14(3):177-80. PubMed ID: 14655061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatoscintiphotography in the diagnosis of liver diseases].
    Makarenko TP; Kasatkin IuN; Upyrev AV; Mironov SP; Esenbaev SR
    Vestn Khir Im I I Grek; 1973 May; 110(5):20-4. PubMed ID: 4777465
    [No Abstract]   [Full Text] [Related]  

  • 38. [Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma].
    Thomas CM; Wobbes T; Bonfrer JM; Peterse JL; Nap M; Beex LV
    Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2354-7. PubMed ID: 8264818
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
    Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Small intestinal mucin antigen (SIMA)].
    Hinoda Y; Akashi H; Imai K
    Nihon Rinsho; 1999 Dec; 57 Suppl():553-5. PubMed ID: 10778189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.